This acquisition is for the immune monitoring of patients with AIDS and with populations with high risk of developing AIDS. Specifically, this acquisition involves the biological assessment of cellular function in those populations in which subset specification and activation markers are identified and will be conducted in two phases. Phase one will bea quarterly assessment of prospective controlled immunologic monitoring of peripheral lymphocyte and non-lymphocyte cellpopulations of AIDS patients. Phase two will be the assessment of cell functions, on a quarterly basis, using monoclonal antibodies to selectively remove different cell populations, and assaying the functions of the remaining cellpopulations.
| Yagi, M J; Chu, F N; Jiang, J D et al. (1992) Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol 63:126-34 |
| Sei, Y; Tsang, P H; Chu, F N et al. (1989) Inverse relationship between HIV-1 p24 antigenemia, anti-p24 antibody and neutralizing antibody response in all stages of HIV-1 infection. Immunol Lett 20:223-30 |
| Sei, Y; Tsang, P H; Roboz, J P et al. (1988) Neutralizing antibodies as a prognostic indicator in the progression of acquired immune deficiency syndrome (AIDS)-related disorders: a double-blind study. J Clin Immunol 8:464-72 |
